A dose-escalation study of recombinant human Lnterleukin-18 using two different schedules of administration in patients with cancer

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3462-3469

  Robertson, Michael J ^a,b   Kirkwood, John M ^c   Logan, Theodore F ^b   Koch, Kevin M ^d   Kathman, Steven ^d   Kirby, Lyndon C ^d   Bell, William N ^d   Weisenbach, Jill ^b   Thurmond, Linda M ^d   Dar, Mohammed M ^d  

^a Lymphoma Program   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IBOCTADEKIN; INTERLEUKIN 18 BINDING PROTEIN; LYMPHOCYTE ANTIGEN; RECOMBINANT INTERLEUKIN 18; ANTIBODY; ANTINEOPLASTIC AGENT; INTERLEUKIN 18; RECOMBINANT PROTEIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPESTHESIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; RASH; SIDE EFFECT; SKIN MANIFESTATION; THORAX PAIN; TREATMENT RESPONSE; URTICARIA; VOMITING; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; IMMUNOLOGY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIBODIES; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 50349092728     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4740     Document Type: Article

References (16)

1. Nakanishi K, Yoshimoto T,Tsutsui H, Okamura H. Inter-leukin-18 regulates bothTh1 and Th2 responses. Annu Rev Immunol 2001;19:423-74.
2. Gracie JA, Robertson SE, Mclnnes IB. lnterleukin-18. J Leukoc Biol 2003;73:213-24.
3. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002;14:117-22.
4. Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production byTcells. Nature 1995;378:88-91.
5. Robinson D, Shibuya K, Mui A, et al. IGIF does not driveTh1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity 1997;7:571-81.
6. YoshimotoT, Takeda K.TanakaT, et al. IL-12 upregu-lates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998;161:3400-7.
7. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997;57:4557-63.
8. Osaki T, PeronJ-M, Cai Q, et al. IFN-γ-inducing fac-tor/IL-18 administration mediates IFN-γ- and IL-12-in-dependent antitumor effects. J Immunol 1998;160: 1742-9.
9. Hashimoto W, Osaki T, Okamura H, et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999;163:583-9.
10. Wigginton JM, Lee J-K, Wiltrout TA, et al. Synergistic enhancement of ineffective endogenous antitumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002;169:4467-74.
11. Coughlin CM, Salhany KE, Wysocka M, et al. Inter-leukin-12 and interleukin-18 synergistically induce mu-rine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998:101:1441-52.
12. Robertson MJ, Mier JW, Logan T, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006:12:4265-73.
13. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleu-kin 2. JAMA 1994;271:907-13.
14. Siegel JP, Puri RK. lnterleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
15. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997;90:2541 -8.
16. Son Y-l, Dallal RM, Mailliard RB, Egawa S, JonakZL, Lotze MT. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res 2001:61:884-8.